Description
Seeking adults with newly diagnosed Multiple Myeloma (NDMM) that can't be treated with autologous stem cell transplantation for a study of an investigational drug called Belantamab Mafodotin added to treatment with Lenalidomide and Dexamethasone.
Overview
Participants in this study will be randomized to get either a Belantamab Mafodotin infusion or Daratumumab injection added to Lenalidomide and Dexamethasone treatment. Treatment cycles for Belantamab Mafodotin are every 8 weeks initially then every 12 weeks. Treatment with Daratumumab are weekly for 2 months, then every two weeks for 4 months and then once every 4 weeks. Participants getting Belantamab Mafodotin will need to have an eye exam before each dose.
What we're hoping for
We are comparing the investigational drug Belantamab Mafodotin to Daratumumab when added to Lenalidomide and Dexamethasone treatment for Multiple Myeloma that can't be treated with autologous stem cell transplantation on long term survival.
Additional Information
ClinicalTrials.gov Identifier: NCT06679101